A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma

NCT06022861 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

510

Enrollment

INDUSTRY

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: LY01015
DRUG: Fluorouracil
DRUG: Cisplatin
DRUG: Opdivo®

Sponsor

Shandong Boan Biotechnology Co., Ltd